Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

NCT02106390 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02106390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02106390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
June 5, 2014
Completion date
October 14, 2016
Enrollment
750 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal